GGTI-2418 NEW
| Price | $48 | $113 | $189 |
| Package | 1mg | 5mg | 10mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2025-11-04 |
Product Details
| Product Name: GGTI-2418 | CAS No.: 501010-06-6 |
| Purity: 99.18% | Supply Ability: 10g |
| Release date: 2025/11/04 |
Product Introduction
Bioactivity
| Name | GGTI-2418 |
| Description | GGTI-2418 is a highly potent, competitive, and selective inhibitor of geranylgeranyltransferase I (GGTase I), exhibiting inhibitory activities with IC50 values of 9.5 nM for GGTase I and 53 μM for FTase, respectively. Additionally, it enhances p27(Kip1) expression and induces significant regression of breast tumors. |
| In vitro | In HeLa cells, GGTI-2418 (10-15 μM; 16 hours) can delocalize FBXL2 and stabilize IP3R3[2]. |
| In vivo | GGTI-2418 (100 mg/kg daily; 5 days) induces regression of ErbB2-driven mammary tumors in ErbB2 transgenic mice. GGTI-2418 inhibits the geranylgeranylation of Rap1, significantly reduces Akt S473 phosphorylation, and upregulates p27 levels in vivo. Additionally, GGTI-2418 (100 mg/kg daily or 200 mg/kg every third day; 15 days) significantly inhibits the growth of MDA-MB-231 breast tumor xenografts in nude mice. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 100 mg/mL (226.49 mM), Sonication is recommended. 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 4 mg/mL (9.06 mM), Sonication is recommended. |
| Keywords | GGTI-2418 | GGTI 2418 | GGTase I | FTase |
| Inhibitors Related | Stavudine | Cysteamine hydrochloride | Sodium 4-phenylbutyrate | Metronidazole | Citric Acid Triammonium | Tributyrin | L-Methionine | Sodium citrate | Cystamine dihydrochloride | L-Ascorbic acid sodium salt | Alginic acid | Dextran sulfate sodium salt (MW 5000) |
| Related Compound Libraries | Bioactive Compound Library | Anti-Breast Cancer Compound Library | Metabolism Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library | Anti-Cancer Active Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $2500.00/100mg |
VIP2Y
|
TargetMol Chemicals Inc.
|
2025-10-27 | |
| $1980.00/25mg |
VIP4Y
|
TargetMol Chemicals Inc.
|
2025-08-21 | |
| $99.00/1EA |
Amikon Limited
|
2018-11-22 | ||
| $48.00/1mg |
VIP4Y
|
TargetMol Chemicals Inc.
|
2025-11-04 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY